A Pharmaceutical Composition Comprising A Liposomal Formulation Of Efavirenz, Its Preparation And Application Thereof
DOI:
https://doi.org/10.52783/jns.v14.3546Keywords:
antiviral, DDS, Efavirenz, ARVs, poorly soluble drugAbstract
In many countries, Efavirenz is the primary non nucleotide reverse transcriptase inhibitor for first-line antiretroviral therapy. It is an orally active antiviral drug that is specific for human immunodeficiency virus type 1 (HIV-1). Its effectiveness is due to its lengthy half-life, which ranges from 52 to 76 hours after numerous doses. The medication is poorly soluble in water. One of the most difficult difficulties for formulation scientists in the research sector will be the oral delivery of poorly soluble drugs. We intended to investigate effective encapsulation of efavirenz (EFV, which is one of the powerful (ARVs) using varied mass ratios of crude soybean lecithin and cholesterol, since the liposome is the most clinically successful DDS and yet is often investigated for ARVs delivery
Downloads
Metrics
References
Brahmankar D, Jaiswal S. Bio pharmaceutics and Pharmacokinetics a Treatise. 2nd ed. 2011: 303-308
Sinko PJ. Martin's Physical Pharmacy And Pharmaceutics Sciences, Lippincott, Williams and Wilkins.6th ed. 2011: 347-349
Barar FS. Essentional of Pharmacontherapeutics. Chand and company Ltd. 6 th ed.2009: 27-28
Kant Shashi. A complete Review on Liposomes. International Journal of Research Pharmacy, 2012; 3(7):10-16.
Sharma Shailesh, Sharma Neelam, Kumar Sandeep, Gupta GD. Liposomes: A Review J. Of Pharm Res 2009; 2(7):1163-1167.
Maluta S. Mufamadi. A Rev won Composite Liposomal Technologies for Specialized Drug Delivery J. of Drug Delivery, 2011:1-19.
Rutuja Ravindra Deshmukh. A review on: liposomes. World Journal of Pharmacy and Pharmaceutical Sciences; Volume 5, Issue 03, 506-517.
Saraswathi Marripati. A Review on Liposome. International Journal of Research in Pharmaceutical and Nano Sciences, 2014; 3(3):159 - 169.
Upendra Bulbake. Liposomal Formulations in Clinical Use: An Updated Rev. Pharm 2017; 9(12):1-33.
Robert M. Silverstein, Francis X. Webster, David J. Kiemle DLB., (2014). Spectrometric Identification of Organic Compounds. 8th ed. Wiley Publisher
Ajith K Nangare. et al., Development and validation of UV spectrophotometric methods for estimation of Efavirenz in bulk and tablet dosage form, Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. 2(3), 2014, 134 - 144.
Deshpande Anant N., Spectrophotometric Estimation of Efavirenz in Formulation and Biological Fluid, Int. J. Res. Pharm. Sci. Vol-1, Issue-4, 2010, 402-406.
Sathish N. K. et al., Quantitative determination of Efavirenz in bulk drug and formulation by colorimetry, Advances in Applied Science Research, 2014, 5(4):176-180
Kumar YA, Rao NR. (2010). Development of Rapid UV Spectrophotometric Method for the Estimation of Efavirenz in Formulations. E-Journal Chem.; 7(3):856-860.
Kadam AA, Babu CJG, Permal RV, Channabasavaraj K, Mani TT. (2012) Development and Validation of Method for the Quantitative Estimation of Efavirenz in Bulk and Phrmaceutical Dosage Form. Am J PharmTech Res.; 2(1):324-330.
Kamble RN, Mehta P., (2015). Development of simple HPLC method to estimate the blood plasma concentration of Efavirenz in rat after oral administration, Innovare Academic Sciences, Int. J Pharm & Pharm. Sci.;7(7):7-10.
Saras-Nacenta M, López-Púa Y, Lípez-Cortés LF, Mallolas J, Gatell JM, Carné X., (2001). Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl.;763(1-2):53-59
Monica R. P. Rao and Laxmi S. Babrekar. Liposomal Drug Delivery for Solubility and Bioavailability Enhancement of Efavirenz. Indian J Pharm Sci 2018;80(6):1115-1124
T. Veena. Formulation and evaluation of liposomal drug delivery system of decitabine. Int. J. of Pharmacy and Analytical Research Vol-6(3) 2017, 519-525
Dr. B. Bindu Madhavi. Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniques. International Journal of Pharmaceutical Investigation, January 2011, Vol 1, Issue 1, 29-34
Bandela Anusha and M. Sunitha Reddy. Formulation and In Vitro Evaluation of Efavirenz Loaded Liposomes. International Journal of Pharmacy and Biological Sciences-IJPBS (2019) 9 (1): 580-592
Rangasamy Pasupathy, Pitchaimuthu Pandian, Subramanian Selvamuthukumar. Formulation Development and Characterization of Liposomes for Sorafenib Delivery. International Journal of Scientific & Technology Research Volume 9, Issue 01, JANUARY 2020. 2283-2286
Devi R. Formulation, characterization and evaluation of fluconazole liposomes. Pelagia Research Library Der Pharmacia Sinica, 2015, 6(5):61-66
Debatri Roy, Sudipta Das. Design and In Vitro Release Kinetics of Liposomal Formulation of Acyclovir. Int J App Pharm, Vol 11, Issue 6, 2019, 61-65
Krishna Mohan Chinnala. Formulation and Evaluation of Acyclovir Liposomes. International Research Journal of Pharmaceutical and Biosciences (IRJPBS) 4 (1) 5-15
Prabhu. Rabhu, Y., Rao, K., Kumar, V. and Kumari, B. (2014) X-Ray Analysis by Williamson-Hall and Size-Strain Plot Methods of ZnO Nanoparticles with Fuel Variation. World Journal of Nano Science and Engineering, 4, 21-28.
M.Sumithra. Characterization of SnO2 Nanoparticles in the traditionally prepared Ayurvedic medicine. International Conference on Nano Science & Engineering Applications. ICONSEA-2014. Materials Today: Proceedings 2 ( 2015 ) 4636 – 4639
Senthilkumar K, Ezhilmuthu R. Preparation and cheracterization of Nabumetone liposome. Int. J. Life Sci Bt and Pharm Res.2012 Jan; 1(1): 2250-3137
Vyas L.taper K.Development and Cherterization of topical liposomal gel formulation for anti-cellute activity. Int J Pharm Pharm Sci. 2013; 5(3): 512-516
B.N. Vedha Hari Engineered polymeric nanoparticles of Efavirenz: Dissolution enhancement through particle size reduction. Chemical Engineering Science 155 (2016), 366–375
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
